Canada Markets closed

Can-Fite BioPharma Ltd. (CANF)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.8942-0.0058 (-0.64%)
At close: 03:59PM EDT
Full screen
Loading interactive chart...
  • Business Wire

    Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update

    PETACH TIKVA, Israel, May 26, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022.

  • Business Wire

    Can-Fite Granted Key NASH Patent in Israel

    PETACH TIKVA, Israel, May 16, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted by the Israel Patent Office.

  • Business Wire

    Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit

    PETACH TIKVA, Israel, May 02, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s CEO Dr. Pnina Fishman has been invited as an expert speaker to deliver a presentation titled "Targeting the A3 Adenosine Receptor for the Treatment of Advanced Liver Cancer" at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in